MOESM3 of Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy Teofila Seremet Yanina Jansen Simon Planken Hassan Njimi Mélanie Delaunoy Hakim El Housni Gil Awada Julia Schwarze Marleen Keyaerts Hendrik Everaert Danielle Lienard Véronique Marmol Pierre Heimann Bart Neyns 10.6084/m9.figshare.9777104.v1 https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Undetectable_circulating_tumor_DNA_ctDNA_levels_correlate_with_favorable_outcome_in_metastatic_melanoma_patients_treated_with_anti-PD1_therapy/9777104 Additional file 3: Table S1. Longitudinal monitoring of patients with progressive disease exclusively in the central nervous system. Table S2. Absolute values of longitudinal monitoring of patients with > 500 copies of mutated ctDNA/ml of plasma at baseline and/or at week 3. 2019-09-06 04:32:19 Translational research Liquid biopsy Circulating tumor DNA Monitoring Immunotherapy Metastatic melanoma BRAF/NRAS mutations monitoring